Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop FX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

Overall MarketRank^™

1.57 out of 5 stars

Medical Sector

437th out of 2,041 stocks

Pharmaceutical Preparations Industry

206th out of 769 stocks

3.5 Analyst's Opinion

Consensus Rating
Xenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.25, Xenon Pharmaceuticals has a forecasted upside of 36.4% from its current price of $18.51.
Amount of Analyst Coverage
Xenon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Xenon Pharmaceuticals has received 365 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Xenon Pharmaceuticals has received 313 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Xenon Pharmaceuticals has received 53.83% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote “Outperform” if you believe XENE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Xenon Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Xenon Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Xenon Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.35% of the stock of Xenon Pharmaceuticals is held by insiders.
Percentage Held by Institutions
79.90% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($0.87) to ($1.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Xenon Pharmaceuticals is -19.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Xenon Pharmaceuticals is -19.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Xenon Pharmaceuticals has a P/B Ratio of 6.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

Is Xenon Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xenon Pharmaceuticals stock.
View analyst ratings for Xenon Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Xenon Pharmaceuticals?

Wall Street analysts have given Xenon Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Xenon Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for Xenon Pharmaceuticals.

How can I listen to Xenon Pharmaceuticals' earnings call?

Xenon Pharmaceuticals will be holding an earnings conference call on Tuesday, May 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its quarterly earnings results on Monday, March, 1st. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. The biopharmaceutical company earned $5.15 million during the quarter, compared to the consensus estimate of $3.50 million. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 21.76% and a negative net margin of 102.25%.
View Xenon Pharmaceuticals' earnings history.

How has Xenon Pharmaceuticals' stock price been impacted by COVID-19?

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XENE stock has increased by 45.8% and is now trading at $18.53.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for XENE?

5 brokers have issued 1-year target prices for Xenon Pharmaceuticals' shares. Their forecasts range from $23.00 to $28.00. On average, they expect Xenon Pharmaceuticals' share price to reach $25.25 in the next year. This suggests a possible upside of 36.3% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the following people:

Dr. Simon N. Pimstone, CEO & Director (Age 53, Pay $811.28k)
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A., MBA, CPA, CMA, Pres, CFO & Company Sec. (Age 45, Pay $684.83k)
Dr. Ernesto Aycardi-Fonseca M.D., Chief Medical Officer (Age 57, Pay $654.78k)
Ms. Jodi Regts M.B.A., B.A., MBA, VP of Corp. Affairs & Investor Relations
Ms. Shelley McCloskey, Sr. VP of HR (Age 61)
Mr. Robin P. Sherrington, Exec. VP of Strategy & Innovation (Age 60)
Dr. James R. Empfield, Sr. VP of Drug Discovery (Age 60)
Ms. Sheila M. Grant M.B.A., M.Sc., MBA, Sr. VP of R&D Operations
Dr. Christopher Von Seggern M.B.A., M.P.H., Ph.D., M.P.H. M.B.A, Chief Commercial Officer

Who are some of Xenon Pharmaceuticals' key competitors?

Some companies that are related to Xenon Pharmaceuticals include MorphoSys (MOR), Taro Pharmaceutical Industries (TARO), PTC Therapeutics (PTCT), Cryoport (CYRX), Pacira BioSciences (PCRX), Intra-Cellular Therapies (ITCI), OPKO Health (OPK), Rocket Pharmaceuticals (RCKT), Organogenesis (ORGO), Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), ALX Oncology (ALXO), Global Blood Therapeutics (GBT), Prestige Consumer Healthcare (PBH) and Xencor (XNCR).
View all of XENE's competitors.

What other stocks do shareholders of Xenon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Swiss National Bank (0.16%), Quantitative Systematic Strategies LLC (0.06%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone.
View institutional ownership trends for Xenon Pharmaceuticals.

Which institutional investors are selling Xenon Pharmaceuticals stock?

XENE stock was sold by a variety of institutional investors in the last quarter, including Quantitative Systematic Strategies LLC.
View insider buying and selling activity for Xenon Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Xenon Pharmaceuticals stock?

XENE stock was purchased by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank , and Swiss National Bank.
View insider buying and selling activity for Xenon Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $18.53.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals has a market capitalization of $759.04 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-41,600,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals employs 123 workers across the globe.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is www.xenon-pharma.com.

Where are Xenon Pharmaceuticals' headquarters?

Xenon Pharmaceuticals is headquartered at 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]

This page was last updated on 5/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Xenon Pharmaceuticals Stock Forecast, Price & News

Adding

Adding

Adding Xenon Pharmaceuticals Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Headlines

About Xenon Pharmaceuticals

MarketRank™

Overall MarketRank™